88 related articles for article (PubMed ID: 8999686)
1. [Efficacy of herpetic vaccine, larifan, myelopid and their combinations during herpesvirus infection in irradiated animals].
Alimbarova LM; Barinskiĭ IF
Vopr Virusol; 1996; 41(6):270-4. PubMed ID: 8999686
[TBL] [Abstract][Full Text] [Related]
2. [Experience with the combined treatment of recurrent herpes using larifan and a herpetic vaccine].
Potekaev NS; Nosik NN; Samgin MA; Kudratullaev KN; Lavrukhina LA
Klin Med (Mosk); 1992 Jan; 70(1):67-70. PubMed ID: 1318984
[TBL] [Abstract][Full Text] [Related]
3. [The efficiency of combined therapy of herpes virus infection in HIV infected patients].
Papuashvili MN; Shchelkanov MIu
Vopr Virusol; 2004; 49(2):25-9. PubMed ID: 15106380
[TBL] [Abstract][Full Text] [Related]
4. [Study of an experimental herpesvirus infection during irradiation].
Alimbarova LM; Lavrukhina LA; Barinskiĭ IF
Vopr Virusol; 1996; 41(5):228-32. PubMed ID: 8967071
[TBL] [Abstract][Full Text] [Related]
5. [The use of immunostimulants for enhancing the immunogenicity of a herpes vaccine].
Barinskiĭ IF; Semenova TB; Posevaia TA; Alimbarova LM; Kolieva MKh; Shabalina NV
Vopr Virusol; 1993; 38(6):274-6. PubMed ID: 8303890
[TBL] [Abstract][Full Text] [Related]
6. [Effectiveness of Soviet derivatives of phosphonic acid and their combination with interferon inducers in cell cultures and in a model of herpetic meningoencephalitis in mice].
Samoĭlovich EO; L'vov ND; Chepaĭkina TA; Lidak MIu; Tsvetkov EN; Bobkov AF; Garaev MM; Barinskiĭ IF
Vopr Virusol; 1989; 34(4):466-74. PubMed ID: 2555965
[TBL] [Abstract][Full Text] [Related]
7. [Immunopharmacological analysis of secondary postradiation immunodeficiency].
Ivanov AA; Deshevoĭ IuB; Karpova NA; Lebedev VG; Leonenko IV; Stavrakova NM; Tazulakhova EB; Ulanova AM; Khaustova LI; Shal'nova GA
Radiats Biol Radioecol; 1994; 34(4-5):482-8. PubMed ID: 7951873
[TBL] [Abstract][Full Text] [Related]
8. [Antiviral activity of the natural immunostimulant "Vegetan" in murine herpetic meningoencephalitis, guinea pig genital herpes, and canine parvoviral enteritis].
L'vov ND; Chekanovskaia LA; Alimbarova LM; Mel'nikov VR; Zontov SV; Slepushkin VA; Barinskiĭ IF
Vopr Virusol; 1995; 40(2):85-9. PubMed ID: 7762239
[TBL] [Abstract][Full Text] [Related]
9. [Stimulating effect of myelopid on the regeneration of the medullary hematopoiesis in experimental acute radiation sickness].
Deshevoĭ IuB; Moroz BB; Lebed' VG; Stepanenko RN
Radiats Biol Radioecol; 1994; 34(4-5):561-4. PubMed ID: 7951884
[No Abstract] [Full Text] [Related]
10. [The antiviral activity of peptide immunomodulator "Gepon" in experimental infections caused by herpes simplex viruses types 1 and 2].
Barinskiĭ IF; Alimbarova LM; Lazarenko AA; Ataullakhanov RI
Vopr Virusol; 2003; 48(5):30-3. PubMed ID: 14598478
[TBL] [Abstract][Full Text] [Related]
11. The effect of UV-B irradiation on secondary epidermal infection of mice with herpes simplex virus type 1.
El-Ghorr AA; Norval M
J Gen Virol; 1996 Mar; 77 ( Pt 3)():485-91. PubMed ID: 8601786
[TBL] [Abstract][Full Text] [Related]
12. [Use of vaccine interferonogens for treating dermato-neurological syndromes of herpetic etiology].
Mikhaĭlenko AA
Tr Inst Im Pastera; 1985; 62():128-30. PubMed ID: 3035754
[No Abstract] [Full Text] [Related]
13. Recombinant herpes simplex virus type 1 (HSV-1) codelivering interleukin-12p35 as a molecular adjuvant enhances the protective immune response against ocular HSV-1 challenge.
Osorio Y; Ghiasi H
J Virol; 2005 Mar; 79(6):3297-308. PubMed ID: 15731224
[TBL] [Abstract][Full Text] [Related]
14. [Protective effect of a commercial vaccine, poludan and their combinations in an experimental herpes infection].
Khaletskaia EV; Fadeeva LL; Selezneva AIu; Semenova TB
Zh Mikrobiol Epidemiol Immunobiol; 1987 Feb; (2):51-4. PubMed ID: 2437741
[TBL] [Abstract][Full Text] [Related]
15. [The antiviral activity of a number of Soviet chemical preparations and the interferon inducer larifan and their combinations in a model of experimental genital herpes in guinea pigs].
L'vov ND; Samoĭlovich EO; Tikhonchuk IA; Vanag AI; Lidak MIu; Chepaĭkina TA; Tsvetkov EN; Barinskiĭ IF
Vopr Virusol; 1990; 35(4):338-42. PubMed ID: 2256320
[TBL] [Abstract][Full Text] [Related]
16. Intravascular naked DNA vaccine encoding glycoprotein B induces protective humoral and cellular immunity against herpes simplex virus type 1 infection in mice.
Cui FD; Asada H; Kishida T; Itokawa Y; Nakaya T; Ueda Y; Yamagishi H; Gojo S; Kita M; Imanishi J; Mazda O
Gene Ther; 2003 Dec; 10(25):2059-66. PubMed ID: 14595378
[TBL] [Abstract][Full Text] [Related]
17. Cytokine genetic adjuvant facilitates prophylactic intravascular DNA vaccine against acute and latent herpes simplex virus infection in mice.
Cui FD; Asada H; Jin ML; Kishida T; Shin-Ya M; Nakaya T; Kita M; Ishii M; Iwai M; Okanoue T; Imanishi J; Mazda O
Gene Ther; 2005 Jan; 12(2):160-8. PubMed ID: 15470476
[TBL] [Abstract][Full Text] [Related]
18. [Study of the effectiveness of recombinant alpha2-interferon and its inducers in primates with orthopoxvirus infection].
Loginova SIa; Bogatikov GV; Prikhod'ko AV; Polozov AI
Vopr Virusol; 1997; 42(4):186-8. PubMed ID: 9304302
[TBL] [Abstract][Full Text] [Related]
19. [Current aspects of the problem of specific therapy for herpetic lesions of the central nervous system].
Votiakov VI; Kolomiets AG
Vestn Akad Med Nauk SSSR; 1988; (5):3-12. PubMed ID: 2845678
[No Abstract] [Full Text] [Related]
20. [Combined use of antiviral preparations].
Ershov FI; Chizhov NP
Vopr Virusol; 1984; 29(6):644-56. PubMed ID: 6084895
[No Abstract] [Full Text] [Related]
[Next] [New Search]
